Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings.

Stabinski L, OʼConnor S, Barnhart M, Kahn RJ, Hamm TE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S274-85. doi: 10.1097/QAI.0000000000000496. Review.

PMID:
25768867
2.

Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential?

Jazwa A, Coleman MS, Gazmararian J, Wingate LT, Maskery B, Mitchell T, Weinberg M.

Vaccine. 2015 Mar 10;33(11):1393-9. doi: 10.1016/j.vaccine.2015.01.010. Epub 2015 Jan 14.

3.

Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, Sun X, Zhang L, Lv J, Yang F.

Hum Vaccin Immunother. 2014;10(10):2983-91. doi: 10.4161/hv.29944.

PMID:
25483678
4.

Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.

Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME.

J Antimicrob Chemother. 2015 Feb;70(2):396-404. doi: 10.1093/jac/dku404. Epub 2014 Oct 31. Review.

PMID:
25362571
5.

Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome.

Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL.

World J Gastroenterol. 2014 Oct 21;20(39):14142-55. doi: 10.3748/wjg.v20.i39.14142. Review.

6.

Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.

Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Oct 21;161(8):546-53. doi: 10.7326/M14-0602.

7.

High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting.

Heidrich B, Cetindere A, Beyaz M, Stahmeyer JT, Basaran MM, Braynis B, Raupach R, Bremer B, Manns MP, Wedemeyer H, Bastürk M.

Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1090-7. doi: 10.1097/MEG.0000000000000164.

PMID:
25076065
8.

Use of entecavir for the treatment of complex forms of hepatitis B.

Sacco R.

Eur Rev Med Pharmacol Sci. 2014;18(9):1333-43. Review.

9.

The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease.

Garnett GP.

Vaccine. 2014 Mar 20;32(14):1536-42. doi: 10.1016/j.vaccine.2013.11.007.

PMID:
24606635
10.

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.

Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M.

BMC Gastroenterol. 2014 Feb 17;14:31. doi: 10.1186/1471-230X-14-31.

11.

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection.

Warner BG, Abbott WG, Rodrigo AG.

Evol Med Public Health. 2014 Jan;2014(1):1-9. doi: 10.1093/emph/eot023. Epub 2013 Dec 13.

12.

Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.

Wright AJ, Fishman JA, Chung RT.

Am J Transplant. 2014 Mar;14(3):629-34. doi: 10.1111/ajt.12598. Epub 2014 Jan 24.

13.

Clinical utility of entecavir for chronic hepatitis B in Chinese patients.

Wang J.

Drug Des Devel Ther. 2013 Dec 12;8:13-24. doi: 10.2147/DDDT.S41423. Review.

14.

Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.

Oliveira GL, Almeida AM, Silva AL, Brandão CM, Andrade EI, Cherchiglia ML, Acurcio Fde A.

Rev Saude Publica. 2013 Aug;47(4):769-78; discussion 779. doi: 10.1590/S0034-8910.2013047004529. English, Portuguese.

15.

Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.

Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C.

PLoS One. 2013 Oct 18;8(10):e78548. doi: 10.1371/journal.pone.0078548. eCollection 2013.

16.
17.

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.

Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R.

Vaccine. 2013 Aug 20;31(37):4024-32. doi: 10.1016/j.vaccine.2013.05.014. Epub 2013 May 22.

PMID:
23707166
18.

Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv.

BMC Infect Dis. 2013 Apr 18;13:181. doi: 10.1186/1471-2334-13-181. Review.

19.

Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment.

Chen SC, Toy M, Yeh JM, Wang JD, Resch S.

Pediatrics. 2013 Apr;131(4):e1135-43. doi: 10.1542/peds.2012-1262. Epub 2013 Mar 25. Erratum in: Pediatrics. 2014 Feb;133(2):346.

20.

Economic evaluation of universal newborn hepatitis B vaccination in China.

Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R.

Vaccine. 2013 Apr 3;31(14):1864-9. doi: 10.1016/j.vaccine.2013.01.020. Epub 2013 Feb 4.

PMID:
23384752
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk